Antibiotics Losing Battle Against Gonorrhea The last line of defense against gonorrhea is losing its effectiveness against the gonorrhea, according to a new article published February 9 in the The New England Journal of Medicine. With no new antibiotics effective against the sexually transmitted infection (STI) on the horizon, Gail Bolan, MD, of the U.S. Centers for Disease Control and her fellow authors, are worried about an upswing in gonorrhea samples showing to be less susceptible to cephalosporins—the only class of drugs active against the bacteria resistant to other standard treatments.
February 08, 2012
Merck Warns of Victrelis and HIV Protease Inhibitor Interactions
The hepatitis C protease inhibitor Victrelis (boceprevir) has some significant drug-drug interactions with common Norvir (ritonavir)?boosted protease inhibitor (PI) combinations, according to preliminary data from a clinical trial and a warning issued to health care providers by Merck on February 6.
February 07, 2012
Spinal Cord Stimulation Shows Potential for Peripheral Neuropathy Electrical stimulation of the spinal cord markedly reduced peripheral neuropathy (PN)associated pain in a man living with HIV who didn’t respond to more conventional PN therapies, according to a February 5 presentation at the 6th World Congress of the World Institute of Pain in Miami and reported by Medscape.
February 06, 2012
CDC Recommends HPV Vaccine for Boys and Young Men, Hep B Vaccine for Diabetics It’s official: All males between 11 and 21 years of age should be vaccinated against human papillomavirus (HPV), a leading cause of oral, genital and anal cancers, according to new U.S. Centers for Disease Control and Prevention guidelines published February 3 in the health agency’s Morbidity and Mortality Weekly Report. HPV vaccination is also recommended for previously unvaccinated men between 22 and 26 years of age who have compromised immune systems, are HIV positive or have sex with other men.
February 02, 2012
Isentress, Intelence, Prezista Regimen Goes the Distance for HIV Treatment Veterans A drug regimen containing Isentress (raltegravir), Intelence (etravirine) and Norvir (ritonavir)boosted Prezista (darunavir) has been shown to be “highly potent and durable in terms of efficacy and safety” in a French clinical trial involving heavily treatment-experienced people living with HIV. According to the research paper published ahead of print by the Journal of Acquired Immune Deficiency Syndromes (JAIDS), 88 percent of those using this regimen had undetectable viral loads after nearly two years of treatment.
More Treatment News
Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.
